Quick Answer: Zepbound (tirzepatide) and Wegovy (semaglutide) are both FDA-approved weekly injections for weight management, but they work through different mechanisms. In the only published head-to-head trial, Zepbound produced greater average weight loss (20.2%) than standard-dose Wegovy (13.7%) over 72 weeks. Since then, Wegovy has expanded significantly: it's now available as a once-daily pill, a higher-dose 7.2 mg injection (Wegovy HD) that comes close to Zepbound's results in its own separate trial, and it carries FDA approvals for cardiovascular risk reduction and liver disease (MASH) that Zepbound doesn't have. Zepbound remains the only one of the two approved specifically for obstructive sleep apnea.
Zepbound vs. Wegovy: How They Work
Both medications belong to a class of drugs called incretin mimetics, which act on gut hormone pathways involved in appetite and blood sugar regulation. The core difference is how many pathways each one targets.
| Feature | Zepbound | Wegovy |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Primary mechanism | GIP + GLP-1 receptor agonist | GLP-1 receptor agonist |
| Standard weight-management form | Weekly injection | Weekly injection |
| Oral option | Not currently available | Yes |
| Higher-dose option | Up to 15 mg | 7.2 mg Wegovy HD |
| Diabetes counterpart | Mounjaro | Ozempic |
This difference in mechanism is generally cited as the reason tirzepatide has produced greater average weight loss in trials, though as the newer Wegovy HD data below shows, a higher dose of a single-pathway drug can meaningfully close that gap.
Effectiveness: What the Head-to-Head Trial Actually Showed
For most of these drugs' history, Zepbound and Wegovy were only compared indirectly, using separate clinical trial programs. That changed with SURMOUNT-5, a phase 3b trial published in The New England Journal of Medicine, the first direct comparison between the two drugs in the same study population.
The trial enrolled 751 adults with obesity (or overweight plus at least one weight-related condition) who did not have diabetes. Participants were randomly assigned to receive either tirzepatide (up to 10 mg or 15 mg) or semaglutide (up to 1.7 mg or 2.4 mg), each titrated to its maximum tolerated dose, over 72 weeks.
| Outcome at 72 Weeks | Zepbound | Wegovy |
|---|---|---|
| Average weight loss | 20.2% | 13.7% |
| Difference | 6.5 percentage points in favor of Zepbound | |
| Trial | SURMOUNT-5 | |
| Duration | 72 weeks | |
| Participants | 751 adults without diabetes | |
An Important Caveat: Wegovy HD Was Never Tested Against Zepbound
Since SURMOUNT-5 was conducted, Novo Nordisk has released a higher-dose version of Wegovy, semaglutide 7.2 mg, known as Wegovy HD, approved by the FDA in March 2026. In its own separate trial program (STEP UP), Wegovy HD produced an intention-to-treat average weight loss of about 18.7%, with a best-case, perfect-adherence figure of 20.7%, compared with roughly 15.5% for the standard 2.4 mg dose in that same trial.
| Measure | Wegovy HD | Standard Wegovy |
|---|---|---|
| Dose | 7.2 mg | 2.4 mg |
| Average weight loss | About 18.7% | About 15.5% |
| Best-case / adherence figure | About 20.7% | — |
| Direct comparison with Zepbound? | No | Yes, in SURMOUNT-5 |
That 18.7% to 20.7% range looks close to Zepbound's 20.2%, and it's tempting to conclude the gap between the two drugs has closed. But Wegovy HD has not been directly compared with Zepbound in any published head-to-head trial. The two figures come from entirely separate study populations, protocols, and time periods, so treating them as directly comparable is a common but genuine analytical error worth avoiding. The only true apples-to-apples data that exists is the SURMOUNT-5 comparison against standard-dose Wegovy.
Dosing and Formats: More Options Than Ever
This comparison has changed substantially since early 2026, when Wegovy expanded well beyond its original single injectable form.
| Option | Zepbound | Wegovy |
|---|---|---|
| Injection | Yes | Yes |
| Oral tablet | No | Yes |
| Standard maintenance injection | Up to 15 mg | Up to 2.4 mg |
| Higher-dose injection | 15 mg maximum standard dose | 7.2 mg Wegovy HD |
| Frequency | Weekly injection | Weekly injection or daily oral option |
For anyone who has avoided GLP-1 treatment specifically due to needle aversion, the Wegovy pill removes that barrier entirely, something Zepbound currently doesn't offer in any form.
Approved Uses Beyond Weight Loss
Both drugs have accumulated additional FDA approvals over time, and this is where their profiles have diverged the most:
| Use / Approval | Zepbound | Wegovy |
|---|---|---|
| Chronic weight management | Yes | Yes |
| Cardiovascular risk reduction | Not currently approved for this indication | Yes |
| MASH / liver disease | Not currently approved for this indication | Yes |
| Obstructive sleep apnea | Yes | Not currently approved specifically for this indication |
A large cardiovascular outcomes trial for tirzepatide, SURMOUNT-MMO, is currently underway but isn't expected to report results until 2027, so Zepbound's approved-use profile may look different by then.
Side Effects Comparison
Both drugs share a largely overlapping side-effect profile, since both work through related gut-hormone pathways.
| Side Effect | Zepbound | Wegovy |
|---|---|---|
| Nausea | Common | Common |
| Vomiting | Can occur | Can occur |
| Diarrhea | Common | Common |
| Constipation | Common | Common |
| Abdominal discomfort | Can occur | Can occur |
| Injection-site reactions | Possible | Possible |
Because tirzepatide's dual mechanism produces stronger appetite suppression on average, some people find its gastrointestinal side effects more pronounced during dose escalation. Slower titration schedules are used with both drugs specifically to reduce this risk, and this pattern held true for Wegovy HD as well, where the higher dose introduced a couple of side effects not as prominent at the standard 2.4 mg dose.
Cost Comparison
Pricing changes frequently and depends heavily on insurance coverage, so treat these as a general snapshot rather than a fixed number.
| Cost Factor | Zepbound | Wegovy |
|---|---|---|
| Cash price | Generally comparable to Wegovy | Varies by formulation and program |
| Manufacturer savings | Available for qualifying patients | Available for qualifying patients |
| Insurance coverage | Depends on plan and indication | Depends on plan and indication |
| Pricing stability | Changes frequently based on insurance, manufacturer programs and promotions | |
Without insurance, standard injectable Wegovy (2.4 mg) has generally been priced in the $499 to $549 per month range, with promotional introductory pricing sometimes available on lower starting doses. Wegovy HD has launched around $399 per month for those paying cash, with savings-card pricing as low as $25 per month for those with qualifying commercial insurance. Zepbound's list price without insurance has generally been comparable, with its own manufacturer savings card also offering pricing as low as $25 per month for eligible insured patients, or around $550 per month for cash-pay patients without insurance coverage. Because manufacturer programs, insurance formularies, and promotional pricing shift often, checking current pricing directly with a pharmacy or the manufacturer is the only reliable way to get an accurate number for your specific situation.
Is Zepbound the Same as Ozempic? Is Wegovy the Same as Mounjaro?
This is a common point of confusion, so it's worth untangling directly:
| Brand | Active Ingredient | Primary Brand Relationship |
|---|---|---|
| Zepbound | Tirzepatide | Weight-management brand |
| Mounjaro | Tirzepatide | Diabetes-labeled counterpart to Zepbound |
| Wegovy | Semaglutide | Weight-management brand |
| Ozempic | Semaglutide | Diabetes-labeled counterpart to Wegovy |
So Zepbound is not the same product as Ozempic, they don't even share an active ingredient. Zepbound's diabetes-labeled counterpart is Mounjaro, and Wegovy's diabetes-labeled counterpart is Ozempic.
Which One Might Be Right for You?
This decision belongs with a prescribing physician who can evaluate individual health history, but a few factors commonly guide the conversation:
| Factor | May Favor Zepbound | May Favor Wegovy |
|---|---|---|
| Average weight loss | Stronger result in SURMOUNT-5 | Strong weight-loss effect |
| Oral treatment preference | Not currently available | Oral option available |
| Cardiovascular indication | Not currently approved specifically for this purpose | FDA-approved cardiovascular risk reduction indication |
| MASH / liver indication | Not currently approved specifically for this purpose | FDA-approved indication |
| Obstructive sleep apnea | FDA-approved indication | Not specifically approved for this indication |
| Individual tolerability | Varies substantially from person to person | |
| Insurance coverage | Depends on the individual's insurance plan and eligibility | |
Frequently Asked Questions
Which is more effective, Zepbound or Wegovy?
In the only published head-to-head trial, Zepbound produced greater average weight loss (20.2%) than standard-dose Wegovy (13.7%) over 72 weeks. The newer Wegovy HD (7.2 mg) came close to that figure in its own separate trial, but has not been directly compared with Zepbound.
Which has worse side effects, Wegovy or Zepbound?
Both share a largely similar gastrointestinal side-effect profile. Some patients find Zepbound's effects more pronounced due to its stronger appetite-suppressing mechanism, while Wegovy HD introduced somewhat higher rates of altered skin sensation and hair loss compared to standard-dose Wegovy. Individual tolerance varies considerably either way.
Is Zepbound the same as Ozempic?
No. Zepbound contains tirzepatide; Ozempic contains semaglutide. They're different active ingredients from related but distinct drug classes.
Why are people switching from Wegovy to Zepbound?
The most commonly cited reason is the SURMOUNT-5 trial data showing greater average weight loss with Zepbound over standard-dose Wegovy, along with individual differences in side-effect tolerance and, for some, cost or insurance coverage differences.
Does Wegovy come in pill form?
Yes. The FDA approved an oral version of Wegovy (semaglutide 25 mg tablets) in December 2025, making it the first oral GLP-1 medication approved for weight management. Zepbound remains available as an injection only.
Which GLP-1 has the fastest weight loss?
In the SURMOUNT-5 trial, weight loss differences between Zepbound and standard-dose Wegovy were measurable within four weeks, with Zepbound showing a faster initial rate that continued widening through 72 weeks.
What is Wegovy HD?
Wegovy HD is a higher-dose (7.2 mg) injectable version of semaglutide, FDA-approved in March 2026 for adults who have already tolerated the standard 2.4 mg dose for at least four weeks and need additional weight reduction. It has not been directly compared with Zepbound in a clinical trial.
This article is for general educational purposes and isn't a substitute for professional medical advice. Zepbound and Wegovy are prescription medications with specific eligibility requirements, contraindications, and monitoring needs. Talk to a licensed healthcare provider to determine which option, if either, is appropriate for you.
Sources: The New England Journal of Medicine: SURMOUNT-5 Trial Results · FDA: Zepbound Prescribing Information · Novo Nordisk: Wegovy Pill FDA Approval Announcement · Novo Nordisk: Wegovy HD FDA Approval Announcement · Eli Lilly: Zepbound Sleep Apnea Approval · Clinical Advisor: Wegovy MASH Approval